论文部分内容阅读
目的观察微波联合重组人干扰素治疗慢性宫颈炎伴高危型人乳头瘤病毒(HPV)感染的临床效果。方法选取2013年12月~2015年6月某院收治的慢性宫颈炎伴高危型HPV感染患者120例,按照随机数字表法分为对照组和观察组,每组60例。对照组患者均在月经干净后3~5 d行微波治疗,观察组在微波治疗2 d后隔天每晚睡前阴道后穹隆纳入重组人干扰素α-2b阴道泡腾胶囊1枚,连用10 d为一个疗程(月经期间停药),连续用药3个疗程。比较两组患者治疗6个月后子宫颈糜烂样改变的有效率及HPV阴转率。结果治疗3个疗程后,观察组总有效率为95.0%,高于对照组的80.0%,差异均有统计学意义(χ2=3.55,P<0.05)。观察组高危型HPV感染转阴率为55.0%(33/60),明显高于对照组的35.0%(21/60),差异有统计学意义(χ2=5.67,P<20.05)。结论微波联合干扰素治疗慢性宫颈炎伴高危型HPV感染疗效好,且高危型HPV感染的阴转率高,值得临床推广应用。
Objective To observe the clinical effect of microwave combined with recombinant human interferon in the treatment of chronic cervicitis complicated with high risk human papillomavirus (HPV) infection. Methods A total of 120 patients with chronic cervicitis and high-risk HPV infection admitted in a hospital from December 2013 to June 2015 were randomly divided into control group and observation group according to random number table method, with 60 cases in each group. The patients in the control group were treated with microwave 3 to 5 days after the menstruation was clean. The observation group was treated with vaginal effervescent capsule containing 1 recombinant interferon alpha-2b in the vaginal posterior fornix every night after 2 days of microwave treatment, d for a course of treatment (withdrawal during menstruation), continuous medication 3 courses. The effectiveness of cervical erosion-like changes and HPV negative conversion rate were compared between the two groups after 6 months treatment. Results After 3 courses of treatment, the total effective rate in the observation group was 95.0%, which was higher than 80.0% in the control group (χ2 = 3.55, P <0.05). The negative rate of high-risk HPV infection in the observation group was 55.0% (33/60), which was significantly higher than that in the control group (35.0%, 21/60). The difference was statistically significant (χ2 = 5.67, P <20.05). Conclusion Microwave combined with interferon treatment of chronic cervicitis with high-risk HPV infection is effective, and high-risk HPV infection, high negative conversion rate, worthy of clinical application.